New frontiers in precision medicine for Sjogren’s syndrome
- 1 February 2021
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 17 (2) , 127-141
Abstract
Introduction: Sjögren’s syndrome is a unique systemic autoimmune disease, placed in the center of systemic autoimmunity and at the crossroads of autoimmunity and lymphoproliferation. The diverse clinical picture of the disease, the inefficacy of current biologic treatments, and the co-existence with lymphoma conferring to the patients’ morbidity and mortality force the scientific community to review disease pathogenesis and reveal the major implicated cellular and molecular elements. Areas covered: Biomarkers for early diagnosis, prediction, stratification, monitoring, and targeted treatments can serve as a tool to interlink and switch from the clinical phenotyping of the disease into a more sophisticated classification based on the underlying critical molecular pathways and endotypes. Such a transition may define the establishment of the so-called precision medicine era in which patients’ management will be based on grouping according to pathogenetically related biomarkers. In the current work, literature on Sjogren’s syndrome covering several research fields including clinical, translational, and basic research has been reviewed. Expert opinion: The perspectives of clinical and translational research are anticipated to define phenotypic clustering of high-risk pSS patients and link the clinical picture of the disease with fundamental molecular mechanisms and molecules implicated in pathogenesis.Keywords
Funding Information
- European Union under the Horizon
This publication has 161 references indexed in Scilit:
- Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS CohortPLOS ONE, 2013
- Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseasesProceedings of the National Academy of Sciences, 2012
- Selective localization of T helper subsets in labial salivary glands from primary Sjögren's syndrome patientsClinical and Experimental Immunology, 2012
- Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2011
- Chitinases in the salivary glands and circulation of patients with Sjögren's syndrome: Macrophage harbingers of disease severityArthritis & Rheumatism, 2011
- MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndromeArthritis & Rheumatism, 2011
- Activation of innate immune responses through Toll‐like receptor 3 causes a rapid loss of salivary gland functionJournal of Oral Pathology & Medicine, 2008
- Salivary gland tissue expression of interleukin‐23 and interleukin‐17 in Sjögren's syndrome: Findings in humans and miceArthritis & Rheumatism, 2008
- Salivary proteomic and genomic biomarkers for primary Sjögren's syndromeArthritis & Rheumatism, 2007
- Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndromeClinical and Experimental Immunology, 2007